Molecular Oncology
Volume 3, Issue 3 , Pages 238-247 , June 2009

Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies

Received 16 October 2008 ,Revised 30 December 2008 ,Accepted 22 January 2009.

References 

  1. Agaton C, Falk R, Hoiden Guthenberg I, Gostring L, Uhlen M, Hober S. Selective enrichment of monospecific polyclonal antibodies for antibody-based proteomics efforts. J. Chromatogr. A. 2004;1043:33–40
  2. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2:127–137
  3. Ben-Kasus T, Schechter B, Sela M, Yarden Y. Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol. Oncol. 2007;1:42–54
  4. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA. 1992;89:4285–4289
  5. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421:756–760
  6. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5:317–328
  7. Gelmon, K., Fumoleau, P., Verma, S., Wardley, A., Conte, P.F., Miles, D., Gianni, L., McNally, V.A., Ross, G.A., Baselga, J., 2008. Results of a Phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. Proceedings from ASCO 2008, Abs TBC.
  8. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J. Computat. Graphical Statist. 1996;5:299–314
  9. Larsson K, Wester K, Nilsson P, Uhlen M, Hober S, Wernerus H. Multiplexed PrEST immunization for high-throughput affinity proteomics. J. Immunol. Methods. 2006;315:110–120
  10. Lindskog M, Rockberg J, Uhlen M, Sterky F. Selection of protein epitopes for antibody production. Biotechniques. 2005;38:723–727
  11. Logtenberg T. Antibody cocktails: next-generation biopharmaceuticals with improved potency. Trends Biotechnol. 2007;25:390–394
  12. Menard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J. Cell Physiol. 2000;182:150–162
  13. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64:2343–2346
  14. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 2006;3:269–280
  15. Nilsson P, Paavilainen L, Larsson K, Odling J, Sundberg M, Andersson AC, et al Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling. Proteomics. 2005;5:4327–4337
  16. Pal SK, Pegram M. Targeting HER2 epitopes. Semin. Oncol. 2006;33:386–391
  17. Pal SK, Pegram M. HER2 targeted therapy in breast cancer … beyond Herceptin. Rev. Endocr. Metab. Disord. 2007;8:269–277
  18. Persson M, Gedda L, Lundqvist H, Tolmachev V, Nordgren H, Malmstrom PU, et al. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res. 2007;67:326–331
  19. Popat S, Smith IE. Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects. Nat. Clin. Pract. Oncol. 2008;5:324–335
  20. Portera CC, Walshe JM, Rosing DR, Denduluri N, Berman AW, Vatas U, et al Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin. Cancer Res. 2008;14:2710–2716
  21. Rockberg J, Lofblom J, Hjelm B, Uhlen M, Stahl S. Epitope mapping of antibodies using bacterial surface display. Nat. Methods. 2008;5:1039–1045
  22. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science. 1998;281:363–365
  23. Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science. 1985;229:976–978
  24. Schwenk JM, Lindberg J, Sundberg M, Uhlen M, Nilsson P. Determination of binding specificities in highly multiplexed bead-based assays for antibody proteomics. Mol. Cell. Proteomics. 2007;6:125–132
  25. Sharon J, Liebman MA, Williams BR. Recombinant polyclonal antibodies for cancer therapy. J. Cell Biochem. 2005;96:305–313
  26. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  27. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, et al. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. 2002;8:1720–1730
  28. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001;2:127–137

PII: S1574-7891(09)00019-2

doi: 10.1016/j.molonc.2009.01.003

Molecular Oncology
Volume 3, Issue 3 , Pages 238-247 , June 2009

Article Tools

* Image Usage & Resolution